OBJECTIVES The aim of this study was to test the hypothesis that invasive coronary function testing at time of angiography could help stratify management of angina patients without obstructive coronary artery disease.
C oronary angiography is routinely performed for the investigation of angina. However, up to one-half of all patients with angina have symptoms and/or signs of ischemia and no obstructive coronary artery disease (CAD) (1) . This large, undifferentiated subgroup includes patients with microvascular angina (MVA) and/or vasospastic angina (VSA). These conditions are associated with high morbidity (2) , impaired quality of life (3) , and considerable use of health resources (4) . Furthermore, impaired coronary vasomotion and the propensity to myocardial ischemia may increase longer-term risk for major adverse cardiac events (MACE) (5, 6) .
In the CorMicA (Coronary Microvascular
Angina) trial involving patients with ischemia and no obstructive CAD, we found that an interventional diagnostic procedure (IDP) to rule in or rule out a disorder of coronary vasomotion was feasible and useful. Angina improved more at 6 months in patients whose IDP results were disclosed compared with the blinded control group. We hypothesized that stratified medicine in patients with angina undergoing invasive coronary angiography would benefit patients in the longer term. We thus performed a pre-specified analysis of patientreported outcome measures at 1 year and assessed longer-term MACE.
METHODS STUDY DESIGN. The British Heart Foundation Cor-MicA trial design and 6-month results have been previously published (7, 8) . The study is an investigator-initiated, parallel-group, randomized, sham-controlled trial with blinded outcome assessment. We recruited patients with angina without obstructive coronary disease who were randomized immediately after angiography to the intervention (IDP to identify coronary vasomotion disorders with stratified medical therapy of endotypes) or a control group (blinded invasive coronary function testing with standard-care antianginal agents guided by the attending cardiologist).
PARTICIPANTS. We screened elective adult referrals to 2 large regional hospitals (Golden Jubilee National Hospital and Hairmyres Hospital) providing invasive cardiac services to all patients in the west of Scotland In the intervention group, the cardiologist reappraised the initial diagnosis on the basis of coronary angiography and could change the diagnosis with linked therapy decisions. In the control group, management was guided by coronary angiography and all of the other available medical information, but not the IDP results. Written guidance informed by practice guidelines was provided to physicians in both groups allowing treatment on the basis of the physicians' working diagnoses. This included using results of the IDP if available (Online Table 1 ) (10).
BLINDING AND ADHERENCE. Patients in the control group had their IDPs performed in the same way as those in the intervention group, except that the results were not disclosed to the treating cardiologists. Dr. Touyz has acted as an advisor for Novartis. Dr. McEntegart has a proctoring agreement with Boston Scientific and Vascular (7, 8) . The outcome assessors and statisticians were blinded to treatment group allocation.
Details of the blinding procedure have been described
IDP. The purpose of the IDP was to identify disorders of coronary vasomotion: MVA, VSA, both, or none. (11) . A diagnosis of noncardiac chest pain required no obstructive epicardial CAD (FFR >0.80) and an absence of evidence of any coronary vasomotion disorder (CFR $2.0, index of microcirculatory resistance <25, and negative results on ACh testing). STRATIFIED MEDICAL THERAPY. After randomization and completion of the diagnostic intervention, research staff members invited the cardiologists to consider the new findings and re-evaluate the diagnosis and treatment plan initially made on the basis of angiography alone. The attending cardiologists in both of the groups were provided with written management guidance specific for each endotype and informed by practice guidelines to facilitate personalized treatment that was specifically aligned to their final diagnosis (Online Appendix) (10) . For example, the first-line therapy for MVA incorporates betablockers, and nitrates were not recommended, whereas calcium-channel blockers and consideration of long-acting nitrates were advocated for VSA. The total number of patients randomized was 151 with analysis according to intention-to-treat. There was 98% completion of the primary efficacy endpoint assessment at 6 months and 94% at one year. STATISTICAL METHODS. The study design and sample size calculation have been previously described (7) . 
RESULTS
Between November 2016 and December 2017, we enrolled 391 of 1,386 screened patients (28%) who had been electively referred for invasive coronary angiography with suspected angina (Figure 1) . The baseline characteristics of the participants are described in Table 1 .
The majority of the participants were women (n ¼ 111 [74%]), and the median age was 61 years.
There was a high prevalence of cardiovascular risk factors and preventive medicines, in keeping with an Prior noninvasive stress test results were abnormal in 47% (45 of 95) and 52% (30 of 58) of patients who had abnormal results on exercise stress electrocardiography and radionuclide myocardial perfusion imaging, respectively ( Table 1 ). The mean exercise duration was 6.3 AE 2.6 min with the standard Bruce treadmill exercise test protocol.
Coronary angiography revealed obstructive CAD in 206 patients (53.7%), and 151 of 181 patients (83%) with no obstructive CAD were randomized (n ¼ 75 to the intervention group, n ¼ 76 to the blinded control group). The left anterior descending coronary artery was the target in 88% (n ¼ 132), the right coronary artery in 12 (8%), and the circumflex coronary artery Figure 3 . There were clinically relevant between-group differences in prescribed therapies stratified by endotype at 12 months. Patients in the intervention arm with VSA were more likely to be taking calcium-channel antagonists at 12 months compared with those in the control arm, whereas patients with MVA were more likely to be taking beta-blockers and angiotensinconverting enzyme inhibitors at 12 months compared with those in the control arm ( Table 3) .
Interestingly, there was no significant treatment effect in the noncardiac chest pain group (95% CI: À6.9 P<0.001
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Physical activity assessed using the International Physical Activity Questionnaire-Short Form at 12 months was numerically higher in the intervention group at follow-up, but the differences were not sta- score AE SD. Unpaired Student's t-test for significant difference in DASI score between groups. The estimated difference between the groups and its 95% confidence interval are displayed. (E) Proportion of subjects in each group participating in cardiac rehabilitation or participating in "moderate" or "high" physical activity according to the International Physical Activity Questionnaire (IPAQ). BIPQ ¼ Brief Illness Perception infarction, 3 had cerebrovascular events (2%), 2 (1%) were hospitalized for heart failure, and 9 (6%) experienced unstable angina requiring urgent revascularization or hospitalization. Causes of death were cardiac (heart failure, n ¼ 1) and noncardiac (malignancy, n ¼ 1). These events are detailed in Table 4 .
There were no between-group differences in any of the MACE subtypes during longer term follow-up.
DISCUSSION
We found that angina severity, quality of life, treatment satisfaction, and illness perception improved at 1 year in the stratified therapy intervention group relative to control. We observed mechanistic differences that help explain the treatment effect, notably appropriate stratification of therapy, lower systolic and diastolic BPs relative to control, enhanced participation in cardiac rehabilitation, and nonsignificant trends toward improved functional capacity and physical activity levels in the intervention group (Central Illustration). There were no procedural safety concerns, and MACE were appreciable in the randomized population, with no significant betweengroup differences. Tables 1 and 3 . (26) . Nevertheless, we adopted a stringent approach using unambiguous reference thresholds for disease classification (e.g., CFR cutoff of 2.0 rather than 2.5). The IDP was focused on a single major coronary artery for pragmatic reasons to avoid unnecessarily prolonging the procedure. In patients with microvascular disease, regional variations in myocardial blood flow at rest and during pharmacological hyperemia may be detected by quantitative imaging with positron emission tomography and cardiac magnetic resonance (6, 27) . Importantly, these noninvasive tools have not been validated for diagnosing vasospastic disorders. 
